Thermo Fisher Adds to Specialty-Dx Business with $3.5B Phadia Buy
May 20, 2011
Thermo Fisher Adds to Specialty-Dx Business with $3.5B Phadia Buy
The acquisition, expected to close in the fourth quarter, will give Thermo Fisher Phadia's immunoassay-based allergy testing and autoimmune disease-testing products.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Phadia to Use Aushon 2470 Arrayer for Development of Allergen and Autoimmunity Diagnostics
June 25, 2010 / ProteoMonitor - BGI Aims to Expand Proteomics Services, Purchase 50-Plus New Mass Spectrometers
June 17, 2011 / ProteoMonitor - Big Names Join Clinical Proteomics Push in 2011, Offering Ray of Optimism Amidst Difficult Year
January 6, 2012 / ProteoMonitor - SuppreMol to Use Protagen Biomarker Panel
August 2, 2011 / GenomeWeb Daily News - Hutch, Broad Teams Publish Comprehensive Methods for MS-Based Biomarker Discovery and Verification
July 29, 2011 / ProteoMonitor